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Abstract
During cell proliferation, growth must occur to maintain homeostatic cell size. Here we show that E2F1 is capable of
inducing growth by regulating mTORC1 activity. The activation of cell growth and mTORC1 by E2F1 is dependent on both
E2F1’s ability to bind DNA and to regulate gene transcription, demonstrating that a gene induction expression program is
required in this process. Unlike E2F1, E2F3 is unable to activate mTORC1, suggesting that growth activity could be restricted
to individual E2F members. The effect of E2F1 on the activation of mTORC1 does not depend on Akt. Furthermore, over-
expression of TSC2 does not interfere with the effect of E2F1, indicating that the E2F1-induced signal pathway can
compensate for the inhibitory effect of TSC2 on Rheb. Immunolocalization studies demonstrate that E2F1 induces the
translocation of mTORC1 to the late endosome vesicles, in a mechanism dependent of leucine. E2F1 and leucine, or insulin,
together affect the activation of S6K stronger than alone suggesting that they are complementary in activating the signal
pathway. From these studies, E2F1 emerges as a key protein that integrates cell division and growth, both of which are
essential for cell proliferation.
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Introduction
For many years, the E2F family of transcription factors have
been well known for their ability to regulate cell cycle progression
by coordinating a large group of genes involved in G1 to S phase
transition. However, numerous studies have shown that E2F
activity could also promote the expression of genes that control cell
death, differentiation and development programs [1]. In mam-
mals, the E2F family is composed by eight members and the
diversity found in this family reflects distinct roles in the
transcriptional regulation and cell function. E2F1-3, forming
heterodimers with DP proteins, function primarily as transcrip-
tional activators; in contrast, E2F4-8 act mainly as transcriptional
repressors. E2F transcriptional activity is mainly regulated by the
retinoblastoma protein family. Among the eight members of the
E2F family described, E2F1 is unique in its ability to induce
apoptosis [2].
Although E2F is a key regulator of cell proliferation, its capacity
to control cell growth is uncertain. During proliferation, increase
of mass must occur to maintain homeostatic cell size during each
cell cycle. Growth and cell division are coupled during the cell
cycle; however, both processes are independently regulated. The
question of whether E2F play a role in cell size in mitotic cells has
been studied in depth, mainly in Drosophila. Over-expression of
dE2F accelerates the cell cycle without affecting growth, and leads
to a greater number of smaller cells [3]. From these results and
others, investigators have discarded the idea of any hypothetic
growth function of E2F. Interestingly, in this organism, cellular
growth is controlled by Cyclin D-Cdk4 complex, an upstream
regulator of E2F through the pRb pathway [4]. In mammalian
cells, the role of E2F on growth has been less extensively studied
and is still questionable. Over-expression of E2F1 in the liver does
not produce any increase in hepatocytes’ mass [5]. However, in
contrast to this lack of growth function, E2F1 is found to be
essential for the induction of hypertrophy in C2C12 myoblasts, a
growth process that occurs without cell division [6].
Cellular growth requires modulation of protein synthesis. One
of the rate-limiting steps in this process is the initiation of
translation, a phase in which the mammalian target of the
rapamycin complex1 (mTORC1) signaling pathway plays an
essential role [7]. Activation of the kinase activity of mTORC1
drives phosphorylation and inactivation of the eukaryotic
translation initiation factor 4E-binding protein 4E-BP, a repressor
of translation initiation, and phosphorylation and activation of
ribosomal protein S6 kinase 1 (S6K1) [8,9]. mTORC1 is regulated
by mitogens through a canonical signaling cascade triggered by
the activation of class I PI3K and Akt [10]. Tuberous sclerosis
genes, hamartin (TSC1) and tuberin (TSC2) are involved in this
pathway. Acting as a complex, TSC1 and TSC2 negatively
regulate mTOR1 by inactivating the small G protein Rheb
through TSC2’s GTPase activating protein activity. TSC1 is
necessary for the stabilization of TSC2, preventing its ubiquitin-
mediated degradation. Activation of Akt produces the phosphor-
ylation and inhibition of the TSC1/TSC2 complex [11]. In
addition to Akt, other kinases are capable of phosphorylating
TSC2 and regulating its function in mTORC1 signaling, and
these include: Erk2 and RSK, which inhibit the TSC2 activity,
while AMPK and GSK3b activate it [12,13].
In this study, we demonstrate for the first time that, in addition
to its role in proliferation and apoptosis, E2F1 is capable of
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regulating cellular growth. E2F1 emerges as a key protein that
integrates cell division and growth, essential processes for cell
proliferation.
Results
E2F1 activity induces growth
In order to study the growth effect of E2F1, we developed a
U2OS ER-E2F1 stable cell line in which E2F1 activity is
dependent on the presence of 4-hydroxitamoxifen (OHT) [14].
This system has been extensively used in other E2F1 function
studies [15,16]. The ER-E2F1 fusion protein is expressed in the
cytosol and translocates to the nucleus in the presence of OHT;
expression of the E2F1-regulated gene Bcl-2 was detected to
confirm E2F1 action (Fig. 1A and 1B). We analyzed the relative
cell size by flow cytometry using forward angle light scatter.
Results demonstrated that activation of E2F1 by OHT addition
promotes cell size increase in G1 cells in a time-dependent manner
(Fig. 2A). The change in size observed was similar to that detected
with serum addition (Fig. 2B). Prior studies have demonstrated the
involvement of mTORC1 in the growth cell response to numerous
stimuli [17]. To test whether this kinase participates in the increase
in cell size detected after E2F1 induction, we analyzed the effect of
the well-known mTORC1 inhibitor, rapamycin, on this response.
Results obtained show that the addition of rapamycin completely
blocked the growth effect of E2F1, suggesting that mTORC1 plays
an essential role in this process (Fig. 2B). Addition of rapamycin
did not interfere with the translocation of ER-E2F1 to the nuclei
(Fig. S1). The increase on E2F1 expression found after OHT
addition can be due to the effect on E2F1 protein stabilization that
occurs in this cellular compartment [18].
E2F1, but not E2F3 regulates mTOR1C by a
transcriptional mechanism
In vivo mTORC1 activity was analyzed by measuring the levels
of the phosphorylated form of S6K and 4E-BP. Activation of E2F1
induced the phosphorylation of S6K and 4E-BP at Thr 398 and
Thr 37/46 respectively, which started at 4 h and increased until
12 h following the treatment. Moreover, the increase in S6K
phosphorylation correlated with an increase in S6K activity
measured by phosphorylation of its own target, S6 (Fig. 3A). As
expected, the addition of rapamycin totally abolished S6K
phosphorylation (Fig. 3B). Note that ER alone did not produce
phosphorylation of S6K, excluding the possibility of an artifact
contribution of the ER sequence included in ER-E2F1 fusion
protein (Fig. 3C). The ability of E2F1 to induce the activation of
S6K was also studied in Saos-2 and PC12 cells, demonstrating that
activation of mTORC1 by E2F1 is not a cell type phenomenon
(Fig. 3D). Depletion of E2F1 by siRNA reduced the effect of E2F1
on S6K phosphorylation, which supports its role on the growth
process (Fig. 3E).
We further investigate whether the growth function of E2F1
could be extended to other members of the E2F family [19]. This
possibility was tested by studying the change in mTORC1
activity in response to E2F3, an E2F family member that
possesses exclusively a proliferative function. In contrast to E2F1,
E2F3 was not able to induce the phosphorylation of S6K,
suggesting that E2F growth activity is restricted to individual E2F
members (Fig. 3F). To confirm that E2F3 was functional, we
measured E2F3 transcriptional activity. To this end, we
transiently transfected cells with ER-E2F3 and with an E2F-
reported constructs, and luciferase activity was measured after
OHT addition. The results obtained confirm the functionality of
the E2F3 expression vector used (Fig. S2). Experiments in which
the medium was removed and replaced multiple times during
E2F1 activation demonstrated that activation of S6K by E2F1
was independent of any autocrine/ paracrine growth factors
(Fig. 4).
Interestingly, E2F1 is also the only member of the E2F family of
transcription factors that has a dual function in regulating either
proliferation or apoptosis [20]. Numerous studies have established
that the role of E2F1 in both processes could be a consequence of
its specific capability to transcriptionally modulate essential genes
for both processes. However, studies have shown that a mutant
that lacks the transcriptional activation domain retains the ability
to induce apoptosis, suggesting that E2F1 could also act through a
non-transcriptional mechanism [21]. In order to determine
whether the transactivation domain of E2F1 is required for its
growth function, we studied the effect of an E2F1 mutant (E2F11–
284) lacking the transactivation binding domain of E2F1 on S6K
phosphorylation. The results obtained demonstrate the essential
role of this domain in the growth function of E2F1 (Fig. 5A). To
confirm that E2F1 operates by a transcriptional mechanism, an
E2F1 mutant (E2F1E132) lacking the DNA binding domain was
tested for its ability to induce the phosphorylation of S6K. Over-
expression of E2F1E132 does not promote the phosphorylation of
S6K; thereby confirming that the E2F1 DNA binding domain is
required for its growth function (Fig. 5A). Indeed, analysis of the
relative cell size of cell lines stablely transfected with the E2F11–284
mutant demonstrates that, as expected, OHT addition does not
produce any change on the cell growth (Fig. 5B). Note that E2F1
mutants are expressed at a higher concentration than the wild
Figure 1. Effect of OHT on the translocation of ER-E2F1 to the
nucleus and Bcl-2 expression. (A) Stable ER-E2F1 U2OS cells were
serum-starved (control) and treated with OHT for 6 hours (OHT). Cells
were immunostained for E2F1 protein (red) and DAPI (blue). (B) Stable
ER-E2F1 U2OS cells were serum-starved and treated with OHT at the
indicated times. Expression of the indicated proteins was determined
by Western blot analysis.
doi:10.1371/journal.pone.0016163.g001
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type. Expression of Bcl2 was used as a positive control of the E2F1
regulated gene. Addition of OHT only increased the expression of
Bcl-2 on cells expressing the wild type E2F1 but not in E2F1E132
and E2F11–284 mutants, confirming that mutants are not able to
activate transcription. Interestingly, in untreated cells, the Bcl-2
expression levels were different depending on which E2F1
construct cells had been transfected. This could be due to a
non-transcription effect of E2F1, as has been reported for other
E2F target genes [21]. Works are in progress to study the
molecular basic of this effect.
Activation of mTORC1 by E2F1 is independent of Akt and
is not affected by over-expression of TSC2
In order to understand the mechanism by which E2F1 activates
mTOR, we focused the study in the effect of E2F1 on the TSC/
mTORC1 signaling pathway, the canonical pathway used for the
regulation of growth in the proliferative processes. The obtained
results demonstrate that E2F1 does not regulate the expression of
the main proteins involved in this pathway (Fig. 6A). A critical step
in the regulation of this pathway by mitogens is the phosphory-
lation of TSC2 by Akt. We further investigated whether E2F1
Figure 2. E2F1 control cellular size. (A) ER-E2F1 U2OS cells were serum-starved and treated with OHT at the indicated hours. Size distribution of
G1 phase cells was analyzed by forward light scatter (FSC). (B) Size distribution of G1 phase cells was analyzed after treatment with serum, and OHT in
the presence and absence of rapamycin (rap). Means of forward scatter populations are presented by graph in the left panels.
doi:10.1371/journal.pone.0016163.g002
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Figure 3. Effect of E2F1 on mTOR activity. Expression of the indicated proteins was determined by Western blot analysis. (A) Stable transfected
ER-E2F1U2OS cells were serum-starved and treated with OHT at the indicated hours and with insulin (Ins) for 2 h or with OHT at the indicated hours.
(B) Stable transfected ER-E2F1U2OS cells were serum-starved and treated with OHT (+) or not (2) for 6 h in the presence or absence of rapamycin
(rap). (C) Stable transfected ER U2OS cells were serum-starved and treated with OHT at the indicated hours and with insulin (Ins) for 2 h or with OHT
at the indicated hours. (D) Stable transfected ER-E2F1 SAOS and PC12 cells were serum-starved and treated with OHT (+) or not (2) for 6 h. (E) U2OS
cells were transfected with E2F1 siRNA or non-silencing siRNA, serum-starved and treated with serum (+) or not (2) for 6 h. Quantification of Western
blot from three independent experiments is shown on the right panel. (F) U2OS were transient transfected with the indicated expression vectors.
After serum-starved, cells were treated with OHT (+) or not (2) for 6 h.
doi:10.1371/journal.pone.0016163.g003
E2F1 and Growth
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could activate TSC/mTORC1 signaling through activation of
Akt. Previous reports have strongly indicated this possibility: E2F1
could induce Akt activity through transcription activation of the
adaptor protein Grb2-associated binder [16]. However, phos-
phorylation of S6K induced by E2F1 was detected in conditions
where Akt was not phosphorylated, suggesting that E2F1 does not
regulate the TSC/mTORC1 pathway through activation of Akt
(Fig. 6B). In agreement with this, phosphorylation of TSC2 at
Thr1462, the target of Akt, was not detected at early stages of S6K
activation. Inhibition of Akt expression with Akt1 siRNA did not
change the effect of E2F1 on S6K phosphorylation, demonstrating
that this kinase is not involved in this process (Fig. 6C).
In addition to Akt, Erk signaling could also regulate mTORC1
signaling by phosphorylation of the TSC1/TSC2 complex [13].
As E2F1 was shown to be able to activate Erk by up-regulating the
expression of Ras guanine nucleotide exchange factors, we
investigated whether Erk signaling was implicated in the growth
response of E2F1 [22]. This possibility was discarded due to the
fact that S6K activation was still detected in the presence of the
specific MEK inhibitor PD98059 in the cells (Fig. 6D).
To answer the question whether TSC1/TSC2 complex is
involved in the E2F1 growth response, we determined the effect of
E2F1 on the S6K phosphorylation in the presence of over-
expressed TSC2. As predicted from its negative role on Rheb
activity, over-expression of TSC2 partially repressed the effect of
insulin on the phosphorylation of S6K (Fig. 7A). However, over-
expression of TSC2 did not interfere with the effect of E2F1.
Indeed, E2F1 and insulin together had a stronger effect on the
activation of S6K than alone, implying a complementary pathway
for both signals (Fig. 7B).
E2F1 induces the intercellular localization of mTORC1 to
the late endosomes vesicles
Although TSC1/TSC2 complex is the main regulator of
mTORC1 activity by mitogens, not all the pathways for
mTORC1 activation go through this complex. It has been
recently demonstrated that the Rag family of GTPases are
essential mediators of mTORC1 activation in response to amino
acids. As results of these investigations a model has been proposed
that Rag GTPase regulate the intracellular localization of
mTORC1. In this model, when amino acids are present, RagA
and RagB recruit mTORC1 to the late endosome and lysosomal
compartiments where Rheb is present and capable to interacte
modulating mTORC1 activity [23]. To address whether E2F1
alters the mTOR1C1 targeting into vesicles, we investigated its
subcellular localization under E2F1 induction. In E2F1 induced
cells, more mTOR was found at the large vesicular structures
comparing to non induced condition (Fig. 8A). Immunostaining
studies using different subcellular markers demonstrated that
mTORC1 is localized in enlarged vesicles that contain LAMP2,
indicating its localization on the late endosomes. In contrast, when
mTORC1 localization was compared with that of Golgi marker,
GM130, or the early endosomal EEA1, colocalization was not
observed (Fig. 8B). These data strongly suggest that E2F1 activates
mTORC1 signaling by a mechanism that involves the transloca-
tion of mTORC1 to late endosomes. It is known that recruitment
of mTORC1 to endosomes by the action of amino acid is an
essential step for the activation of mTORC1 by mitogenic signals
[24]. We further investigated whether the activation of mTORC1
by E2F1 requires the presence of amino acids. In the absence of
amino acids, activation of E2F1 activity was not able to induce the
phosphorylation of S6K neither alone nor in the presence of
insulin (Fig. 9A). In contrast, high induction of S6K phosphory-
lation was observed when E2F1 was activated in the presence of
leucine (Fig. 9A). In accordance with this result, translocation of
mTORC1 to endosomes was only markedly detected in conditons
where leucine was present, and futhermore the largest endosome
vesicles were found when E2F1 activity was induced (Fig. 9B).
Discussion
During cell proliferation, growth must occur to maintain
homeostatic cell size. In this study, we showed for the first time
that the mammalian E2F1, in addition to its role in proliferation
and apoptosis, is also involved in cellular growth. The relationship
between cell growth and E2F activity was investigated previously
by others in Drosophila. In contrast to our results, in Drosophila the
over-expression of dE2F accelerates the cell cycle without affecting
growth [3]. The discrepancy between our results and those
obtained using Drosophila could be due to the complexity of
mammalian E2F systems. In Drosophila, the pRb pathway
converges to the regulation of two members of the E2F family of
transcription factors: an activator, dE2F1, and a repressor, dE2F2
[19]. However in mammals, the retinoblastoma signal pathway
regulates the activity of eight different E2F members, with each of
them playing a different role in cellular fate [2]. As a tentative
model, it would be possible that, during the evolution process, E2F
mammal members took on cellular functions that had previously
involved proteins of the retinoblastoma pathway. According to this
model, the growth function of Cyclin D evident in Drosophila would
be partially replaced by E2F1 in mammals [4]. The growth
activity of E2F1 was dependent on both E2F1’s ability to bind
DNA and to activate gene transcription. In accordance with this, a
change in the transcription of E2F1-regulated genes has been
reported in hypertrophy, a growth process that does not require
cell division [6]. It is very likely that, as has been described for the
proliferative and apoptotic functions, E2F1 is capable of inducing
a gene expression program that could determine cellular growth.
Using a candidate protein approach, we investigated proteins
involved in TSC/mTORC1 pathway, which levels of expression
could differ after over-expression of E2F1. We showed that E2F1
did not regulate the expression of any of these clue proteins. The
regulation of mTORC1 activity by mitogens requires Akt
phosphorylation [11]. Interestingly the effect of E2F1 on the
activation of mTORC1 did not depend on Akt phosphorylation.
In fact, E2F1 and insulin together affected the activation of S6K
stronger than alone, and not only that, they resulted in the
reduction of Akt phosphorylation. The reduction could be due to
the inhibitory effect of S6K on Insulin Receptor Susbstrate-1 [25].
Figure 4. Effect of replacing the medium on S6K phosphory-
lation by E2F1. Stable transfected ER-E2F1U2OS cells were serum-
starved and treated with OHT (+) or not (2) at the indicated times.
Replace of medium to the cells were achieved every hour in the indicate
conditions (+) or not (2). Expression of the indicated proteins was
determined by Western blot analysis.
doi:10.1371/journal.pone.0016163.g004
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We also ruled out any role of Erk2 on the activation of mTORC1
by E2F1. As Akt, Erk2 is capable of regulating the mTOR
pathway by phosphorylation and inhibition of TSC2 complex, and
previous studies have demonstrated that the activity of this kinase
is regulated by E2F1 [13,22].
A link between E2F1 and the mTORC1 pathway has been
recently suggested in E2F1 transgenic mouse and human
hepatocellular carcinomas (HCC) [26]. This study shows that
dysplastic liver and hepatocellular carcinomas from transgenic
mouse possess a higher mTORC1 activity together with a higher
Akt phosphorylation than liver from wild type animals. Based on
these results, and in contrast to the results showed here, the
authors suggest an Akt-dependent activation of the mTORC1
cascade by over-expression of E2F1. Discrepancy on the role of
Akt might be due to the fact that the samples analyzed in this study
were obtained from neoplasic and pre-neoplasic tissues. Moreover,
results from this study obtained by knock-down of the E2F1
protein suggest that E2F1 could also modulate Akt and mTORC1
expression. As pointed out above, we did not observed any change
on the expression of these proteins in our experimental conditions.
It is possible that regulation of Akt expression can occur at longer
times after E2F1 induction; however, this will not be the
responsible event for the activation of mTORC1 found at early
moments of E2F1 activation.
In contrast to the effect of insulin on S6K phosphorylation,
over-expression of TSC2 did not interfere with the action of E2F1.
By interacting with Rheb, the TSC2 complex negatively regulates
mTORC1 activity during mitogenic processes. In accordance with
this role, previous studies demonstrate that over-expression of
TSC2 or of the TSC1-TSC2 complex significantly reduces insulin-
stimulated S6K phosphorylation [27]. The results presented in this
study could suggest that the TSC2 complex does not participate in
Figure 5. Effect of E2F1 mutants on mTOR activity and cellular size. (A) Stable transfected ER-E2F1 U2OS cells wild type (Wt) and mutants
(E132, 1–284) were serum-starved and treated with OHT (+) or not (2) for 6 h. Expression of the indicated proteins was determined by Western blot
analysis. (B) Stable transfected ER-E132 mutant (E132) was serum-starved and treated with OHT and serum as indicated. Size distribution of G1 phase
cells was analyzed by forward light scatter (FSC). Means of forward scatter populations are presented by graph in the left panels.
doi:10.1371/journal.pone.0016163.g005
E2F1 and Growth
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the signal transduction pathway activated by E2F1. As has been
reported in several models, Rheb activity is reduced after the over-
expression of TSC2 and essential for controlling mTORC1
activation; therefore, the lack of effect of TSC2 over-expression on
E2F1 mTORC1 activation indicates that E2F1-induced signal
pathway can compensate the inhibitory effect of TSC2 on Rheb
[7,27].
In order to elucidate the mechanism that E2F1 regulates
mTORC1 activity, we investigated the intracellular localization
of mTOR after E2F1 induction. Previous reports demonstrate
that mTOR can be positively modulated by its translocation to
the late endosome and lysosome, compartments where Rheb is
present and capable of interacting with it [23]. This mechanism
of mTORC1 regulation is used by amino acids to control cell
growth [23,24,28]. Our results demonstrated that E2F1 is
capable of inducing the translocation of mTORC1 to late
endosome particles suggesting that this is the mechanism by
which E2F1 regulates mTORC1 activation. How this process
occurs is presently under investigation. One possibility is that
transcriptional E2F1 targets could regulate, directly or indirectly,
genes involved in the regulation of functions of the endosomal
compartment, as per exemple those for the rag proteins.
Interesting recent studies have shown that another transcription
factor, p53, regulates endosomal formation by regulating the
expression of TSAP6, Chmp4C, Caveolin-1 and DRAM [29,30].
Because p53 is regulated by E2F1, it is possible that translocation
of mTOR to late endosome was a p53 dependent process [2].
Moreover, E2F1 could modulate mTORC1 activity through the
modulation of PLD. It has been demonstrated that this activity is
required for Rheb activation of mTORC1 signaling to S6K.
Activation of E2F1-targets genes could regulate PLD activity
directly or by regulating proteins that interact with PLD1: cPKC,
ARF and Rho [31]. Other possibilities should also be considered
in future investigations of the mechanism by which E2F1
regulates mTORC1 activity, such as the involvement of other
regulators of mTOR1 activity (PP2A, MAP4K3 or calcium)
[32,33].
Although E2F1 induced mTORC1 translocation to late
endosomes, this process required the presence of amino acids.
E2F1 alone was not able to replace amino acids in its function to
induce mTORC1 translocation. However it enhanced the process.
As a result of these experiments, we suggest two possible
mechanisms of E2F1 action. E2F1 could be interacting with the
amino acid signaling pathway and potenciating late endosomes
Figure 6. Effect of E2F1 on the TSC/mTOR signal transduction pathway. Expression of the indicated proteins was determined by Western
blot analysis. (A, B) Stable ER-E2F1 U2OS cells were serum-starved and treated with OHT at the indicated hours. (C) Stable ER-E2F1 U2OS cells were
transfected or not with Akt1 siRNA at the indicated concentrations, serum-starved and treated with OHT (+) or not (2) for 6 h. (D) Stable transfected
ER-E2F1U2OS cells were serum-starved and treated with OHT at the indicated times in the presence or absence of PD98059.
doi:10.1371/journal.pone.0016163.g006
E2F1 and Growth
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formation or, E2F1 could be enlarging the endosome vesicles
downstream of amino acid signaling.
From this study, E2F1 emerges as a key protein that integrates
cell division and growth, which are essential for cell proliferation.
We demonstrate for the first time that E2F1, in addition to its role
in proliferation and apoptosis, is capable of regulating cellular
growth. E2F1 regulates cell mass through modulation of mTOR
activity by a mechanism involving the translocation of mTORC1
to the late endosomes. This exciting finding reveals the possibility




U2OS and SAOS cell lines were cultured in DMEM media
containing 10% fetal calf serum [34]. PC12 were cultured in
DMEM media containing 6% fetal calf serum cells and 6% of
horse serum. For ER-fusion proteins experiments, cells were
serum-starved overnight, before 400 nM of 4-hydroxytamoxifen
(Calbiochem, Germany) was added to activate E2F nucleus
translocation. For assays using inhibitors, cells were pre-incubated
for 1 h in serum-starved media in the presence of 5 mM of
rapamycin (Sigma-Aldrich, USA) or 80 mM of PD98059 (Sigma-
Aldrich, USA) prior the addition of 4-hydroxytamoxifen. As and
when required, insulin (Sigma-Aldrich, USA) was added to the
culture for 30 min at the final concentration of 200 ng/ml.
Plasmid constructs and transfections
Plasmids pCMVHAER-E2F1, pCMVHA-E2F1 and pCMVHA-
E2F3 were kindly provided by Dr. Kristian Helin [14]. pcDNA-
HATSC2 was kindly provided by Dr. George Thomas [35].
E2F1(1–284) and E132 plasmid were donated by Dr. Douglas Cress
[20]. The pCMVHAER-E2F3 was obtained by removing the E2F1
coding region of pCMVHAER-E2F1 plasmid and replacing it with
the E2F3, using the Bam H1 restriction site. pCMVCHAER was
Figure 7. Effect of over-expression of TSC2 on the activation of S6K by E2F1. Expression of the indicated proteins was determined by
Western blot analysis. (A) Stable ER-E2F1 U2OS cells were transient transfected or not with HA-TSC2 expression plamid, serum starved and treated
with OHT (+) or not (2), and insulin (+) or not (2) for 6 h. Quantification of Western blot from four independent experiments is shown on the right
panel. Statistically significant differences were obtained by comparison with no transfected HA-TSC2 cells. (B) Additive effects of E2F1 and insulin in
mTOR signaling. (A) ER-E2F1 U2OS cells were serum-starved and treated with OHT (+) or not (2) for 4 hours, and (+) or not (2) with insulin (Ins) for
30 min. Quantification of Western blot from four independent experiments is shown on the right panels. *P,0.05 and ***P,0.001 Statistically
significant differences were obtained by comparison with cells treated with insulin alone.
doi:10.1371/journal.pone.0016163.g007
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obtained by removing the E2F1 coding region and ligating the ends.
pCMVHAER-(1–284) and pCMVHAER-E123 were obtained by
PCR the E2F1 coding region of E2F1(1–284) and E132 plasmids
and then introduced into the BamH1 site of the pCMVCHAER
plasmid.
Plasmids were transfected with Lipofectamin (Invitrogen, USA)
in accordance with the manufacture’s instructions. To obtain the
ER-E2F stable cell lines, cells were re-suspended and incubated in
D-MEM selective medium, containing 10% serum and 750 mg/ml
Geneticin Selective Antibiotic (G418) (Gibco, UK). After 15 days,
the transfected stable cell line was obtained and maintained in the
D-MEM selective medium). 150 nM of E2F1 siRNA (Santacruz
Biotechnology, USA) or non-silencing siRNA (NS siRNA) (Santa-
cruz Biotechnology, USA) was transfected using Lipofectamin, Akt1
siRNA (Ambion, USA) was transfected using the TransIT-siQUES
(Mirus, USA) following manufacture’s instructions. Luciferase
activity was measured using the Luciferase Assay kit in accordance
with the manufacturer’s recommendations (Promega, USA).
Western blotting
Cells were washed and harvested with PBS. Cell pellets were re-
suspended and incubated for 30 min at 4uC in lysis buffer (20 mM
Tris-HCl pH 8.0, 10 mM EDTA, 2.5 mM MgCl2, 1% Triton
X100 with a supplement 1/100 dilution of phosphatase and
Figure 8. Effect of E2F1 on the mTOR localitation. (A) Stable ER-E2F1 U2OS cells were serum-starved and treated with OHT or not for 5 hours
and immunostained for E2F1 (green) and mTOR (red). (B) Stable transfected ER-E2F1U2OS cells were serum-starved and treated with OHT for 5 hours
and immunostained for indicated endogenous proteins.
doi:10.1371/journal.pone.0016163.g008
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protease inhibitor cocktail (Sigma-Aldrich, USA). Equal amounts
of protein lysate were subjected to 10% sodium dodecylsulphate
polyacrylamide gel electrophoresis and electrophoretically trans-
ferred to PVDF membranes. The membranes were then blocked
with 5% non-fat milk and 5% BSA solution in PBS-T (PBS with
0.1% Tween 20) for 1 hour at room temperature and immuno-
blotted for 2–12 hours (information about antibodies is on
supplementary information). Primary antibody and secondary
horseradish peroxidase-conjugated antibody incubations were
performed in 5% non-fat milk and 5% BSA solution in PBS-T.
Blots were developed using an Enhanced Chemiluminescence kit
(Amersham, UK).
Flow cytometry
Cells were serum-starved for 24 hours and then treated as
described in the figure legend. At the indicated time, cells were
collected by trypsinization, washed, re-suspended in cold PBS, and
fixed by addition of ethanol to a final concentration of 70%. Fixed
cells were re-suspended in PBS containing 0.1% Triton, 0.1%
serum and 0.1 mg/ml RNAse (Roche, USA), DNA was labeled
with 0.05 mg/ml of propidium iodide (Sigma-Aldrich, USA) and
incubated for 30 min at 37uC in a dark place. Cells were analyzed
using a flow cytometry (FACScan, Beckton Dickinson) using
WinMDI 2.8 software.
Immunofluorescence analysis
Cells were plated onto glass coverslips and grown under the
indicated conditions. Then, cells were fixed in 4% paraformalde-
hyde for 30 minutes at 4uC, permeabilized with 0,3% Triton X-
100 (Sigma-Aldrich, USA) and glycine 20 mM in phosphate-
buffered saline (PBS) for 10 minutes at room temperature, and
incubated in blocking solution (1% bovine serum albumin in PBS
Figure 9. Effect of Leu on the activation and localitation of mTOR by E2F1. (A) Cells were serum and amino acids starved for 12 hours, and
treated with OHT for 5 hours or/ and with insulin (Ins) or/and leucine (leu) for 30 min. Expression of the indicated proteins was determined by
Western blot analysis. (B) Immunostained for mTOR (red) and LAMP2 (red) was achieved for experimetal conditions described in A.
doi:10.1371/journal.pone.0016163.g009
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glycine 20 mM) for 15 minutes at room temperature. As indicated,
mTOR rabbit monoclonal IgG (Cell Signaling Technology, USA)
diluted in blocking solution at 1:150, or E2F1 mouse monoclonal
IgG (Santa Cruz Biotechnology, USA) diluted at 1:400 or EEA1
mouse IgG, mouse anti-GM130 (BD Biosciences Pharmingen,
USA) or mouse anti-LAMP2 (BD Biosciences Pharmingen, USA)
diluted at 1:300 were incubated for 60 minutes at 37uC. As a
secondary antibody, we used fluorophore-labeled Rhodamine Red
goat anti-rabbit IgG and Alexa Fluor 488 goat anti-mouse IgG
(Molecular Probes, USA), incubated at 1:300 dilution in blocking
solution for 45 minutes at 37uC. For nuclei staining, cells were
then washed for 10 minutes at room temperature in PBS with
1 mg/ml Hoechst 33258 (Molecular Probes). Coverslips were
washed and mounted in Prolong Gold antifade reagent (Molecular
Probes), and cells visualized under fluorescent microscopy.
mTORC1 localization was observed at an excitation/emission
wavelength of 560/580 nm, cell nuclei at 350/460 nm, and the
others proteins marked with the Alexa fluor probe were observed
at 500/520 nm.
Statistic analysis
Data was analysed by GraphPad Prism4 software. Results are
presented as Mean6S.E.M for n= 4. Experimental data sets were
compared by a two-sampled, two-tailed and unequal S.D. Student
t Test. Values of *P,0.05, **P,0.01 and ***P,0.001 were
considered statistically significant.
Supporting Information
Figure S1 Effect of rapamycin on the expression levels
and translocation of ER-E2F1 to the nucleus. Stable ER-
E2F1 U2OS cells were serum-starved and treated with OHT (+)
or not (2) for 6 hours (OHT) in the presence or in the absence of
rapamycin (rap). (A) Expression of the indicated proteins was
determined by Western blot analysis. (B) Cells were immuno-
stained for E2F1 protein (green) and Hoechst stain (blue).
(DOC)
Figure S2 Effect of tamoxifen on E2F3 transcriptional
activity. U2OS cells were transient transfected with ER-E2F3
and [E2F]3-Luc vectors. After serum-starved, cells were treated
with OHT (+) or not (2) for 12 h and luciferase activity was
measured for both conditions. Statistically significant differences
were obtained by comparison with untreated cells.
(DOC)
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